Browse the evidence

Obesity heritability is estimated at 40-70%, driven by over 1000 genetic variants and complex interactions with environmental and epigenetic factors, with early-onset severe obesity strongly linked to specific genetic mutations.

Recognize that obesity has a strong biological basis, with heritability estimates up to 70%. For those with early-onset severe obesity, genetic factors play a major role. This understanding supports the use of targeted therapies and early screening rather than relying solely on lifestyle advice.

Chronic hyperglycemia and oxidative stress induce beta-cell dedifferentiation by altering the balance of PAX4 and ARX gene expression, causing beta-cells to lose insulin-secreting identity and adopt alpha-cell features.

In Type 2 Diabetes, high blood sugar and stress can cause insulin-producing beta-cells to 'forget' their job and turn into glucagon-producing alpha-like cells. This is driven by epigenetic changes to genes like PAX4 and ARX. This loss of identity contributes to worsening blood sugar control, suggesting that therapies aiming to restore beta-cell identity or function could be beneficial.

Tirzepatide attenuates alcohol-induced dopamine release in the nucleus accumbens and induces sustained synaptic depression in the lateral septum.

Tirzepatide's effect on alcohol reward involves reducing dopamine release in the nucleus accumbens and altering synaptic plasticity in the lateral septum.

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of heart failure and kidney disease progression in patients with chronic kidney disease and type 2 diabetes.

If you have type 2 diabetes and kidney disease, ask your doctor about finerenone. It helps protect your kidneys and heart from further damage.

Users of unopposed estrogen were at increased risk of breast cancer after longer-term use.

Practitioners should consider the risks of long-term unopposed estrogen therapy in postmenopausal women.

The highest breast cancer risk was seen in cancers positive for estrogen receptor (ER+) and progesterone receptor (PR+).

Understanding receptor status may help in assessing breast cancer risk in patients using unopposed estrogen.

Genetically predicted higher childhood obesity, adult obesity, and increased fat-free mass are causally associated with a reduced risk of Brugada syndrome.

If you have Brugada syndrome, maintaining a BMI in the upper-normal range and increasing fat-free mass through resistance training may help reduce your risk. This contrasts with general population advice to lose weight, so consult your cardiologist about personalized weight management.

Pharmacological activation of brown adipose tissue using beta-3-adrenoreceptor agonists increases cardiovascular risk (heart rate and blood pressure) without providing weight loss benefits.

Avoid beta-3-adrenoreceptor agonists for weight loss. They increase heart rate and blood pressure and have failed in clinical trials due to side effects.

Acquired hypothalamic obesity (HO) is driven by structural damage to medial hypothalamic nuclei (ARC, PVN), leading to hyperphagia, central insulin/leptin resistance, and reduced sympathetic energy expenditure, resulting in rapid, treatment-resistant weight gain.

If you have hypothalamic obesity due to brain tumor or surgery, standard diet and exercise will likely fail because the brain's 'thermostat' is broken. You need medical interventions that target the specific hormonal pathways (like GLP-1 agonists or MC4R agonists) rather than relying on willpower alone.

SGLT2 inhibitors provide cardioprotection through hemodynamic improvements, specifically by reducing preload and afterload via osmotic diuresis and natriuresis, which decreases ventricular wall tension and myocardial oxygen consumption.

If you have Type 2 Diabetes and heart issues, SGLT2 inhibitors (like empagliflozin or dapagliflozin) are recommended not just for blood sugar, but to physically reduce the workload on your heart by helping your kidneys remove excess fluid and sodium, protecting your heart function.

SGLT2 inhibitors protect kidney function by restoring tubuloglomerular feedback, which reduces glomerular hyperfiltration and intraglomerular pressure, thereby indirectly reducing cardiovascular disease risk.

SGLT2 inhibitors protect your kidneys by reducing pressure inside the kidney filters, which also helps protect your heart, as kidney health is closely linked to heart health.

Menopausal hormone therapy (MHT) containing estrogen does not reduce cardiovascular disease risk and may increase stroke risk in women with type 2 diabetes, making it unsuitable for primary prevention.

Do not use estrogen patches or pills to protect your heart if you have diabetes. While they help with hot flashes, they do not prevent heart attacks and may increase stroke risk. Focus on blood pressure, lipids, and blood sugar control instead.

Postmenopausal hormone therapy (estrogen alone or combined with progestin) is not associated with a significant decrease in the risk of stroke, and may be associated with an increased risk of ischemic stroke.

For postmenopausal women, hormone therapy (estrogen alone or combined) does not reduce the risk of stroke. There is a suggestion of an increased risk of ischemic stroke among users, particularly with higher doses of estrogen.

Higher body mass index (BMI) at age 18 is associated with a lower risk of both premenopausal and postmenopausal breast cancer.

Maintaining a healthy weight in your late teens and early adulthood may offer long-term protection against breast cancer. While extreme leanness is not necessarily better, avoiding being underweight might be beneficial. Focus on overall health rather than extreme thinness.

GIP promotes triglyceride storage in white adipose tissue and may contribute to ectopic fat accumulation (fatty liver) in mice, acting as an obesogenic hormone in this context.

Endogenous GIP promotes fat storage in adipose tissue, particularly with high-sugar/high-fat diets. This 'obesogenic' effect is part of the biological puzzle that dual GIP/GLP-1 drugs must navigate to achieve net weight loss.

In overweight or obese patients with type 2 diabetes and severe insulin resistance, overriding insulin resistance with high-dose exogenous insulin therapy can induce insulin-mediated metabolic stress, leading to myocardial glucolipotoxicity and increased cardiovascular mortality.

If you have type 2 diabetes, are overweight, and struggle with high blood sugar despite lifestyle changes, aggressive insulin therapy might be doing more harm than good by stressing your heart. Instead of forcing glucose levels down with high insulin doses, focus on treatments that reduce the nutrient load (like weight loss or nutrient-offloading drugs) to respect your body's natural insulin resistance.

High-fat diets (HFD) induce insulin resistance in rodents primarily through the accumulation of diacylglycerol (DAG) and ceramides, which inhibit insulin signaling via PKC and PP2A activation respectively.

This explains why high-fat diets can lead to metabolic issues at a cellular level: excess fat storage in organs like the liver and muscle triggers specific molecules (DAG and ceramides) that block insulin's ability to signal for glucose uptake.

Bariatric surgery does NOT significantly reduce the incidence of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma compared to conventional treatment.

While bariatric surgery reduces many obesity-related cancers, it does not appear to significantly lower the risk of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma.

Racial and ethnic minorities, particularly Black and American Indian/Alaskan Native individuals, have significantly lower initiation rates of newer diabetes medications (GLP-1RAs, DPP-4Is, SGLT-2Is) compared to White individuals, independent of socioeconomic factors.

If you are a minority patient with type 2 diabetes, you may face systemic barriers to accessing newer, highly effective medications like GLP-1s or SGLT-2 inhibitors, even if you have insurance. These drugs offer significant cardiovascular and kidney benefits. It is crucial to discuss these options with your provider, understand your insurance formulary, and advocate for yourself, as disparities in initiation are well-documented and often driven by systemic factors rather than medical necessity.

Brainstem cholecystokinin-expressing (CCKAP/NTS) neurons are necessary for GLP-1 receptor agonists to induce conditioned taste avoidance (nausea/aversive effects).

The nausea and aversion caused by GLP-1 medications are mediated by specific brainstem neurons (CCKAP/NTS). Blocking these neurons prevents the aversive response, confirming that nausea is a central brain effect, not just a stomach issue. This knowledge helps in managing expectations and potentially developing strategies to reduce nausea.

Genetic disruption of AMPK-glycogen binding in skeletal muscle (via AMPK beta2 subunit mutation) leads to increased adiposity and impaired glucose handling, whereas disruption in liver (via AMPK beta1 subunit mutation) primarily increases hepatic fat deposition without affecting whole-body glucose handling.

This research highlights that the body's energy sensors (AMPK) rely on glycogen stores for stability. Disrupting this link impairs metabolic health. While this is a genetic model, it suggests that maintaining healthy glycogen stores through balanced carbohydrate intake and regular physical activity is crucial for optimal metabolic function and preventing ectopic fat accumulation.

Traditional nontargeted weight management strategies (lifestyle changes, anti-obesity medications, and metabolic/bariatric surgery) are frequently inadequate for patients with highly penetrant monogenic or syndromic obesity caused by rare genetic variants in the melanocortin-4 receptor (MC4R) pathway.

If you have severe, early-onset obesity and insatiable hunger (hyperphagia) that persists despite strict dieting or surgery, standard approaches may not work because of a genetic disruption in your brain's hunger signals. You should seek genetic testing and specialized care to access targeted therapies (like setmelanotide) that address the root hormonal cause rather than just calories.

Genetically proxied activation of the glucagon-like peptide-1 receptor (GLP1RA) is causally associated with a reduced risk of schizophrenia.

This study suggests that medications activating the GLP-1 receptor (like semaglutide or liraglutide) may lower the risk of developing schizophrenia, primarily through their effect on body weight. For individuals at high risk of schizophrenia who are overweight, using these medications for weight management might offer a dual benefit of metabolic health and reduced psychiatric risk. However, this is based on genetic data, not direct clinical trials, so it should not replace standard psychiatric care.

Non-sulfated CCK peptides stimulate gastric acid secretion via CCK2 receptors, acting similarly to gastrin, whereas sulfated CCK inhibits acid secretion via CCK1 receptors.

The form of CCK matters. In rare tumors (CCKoma), non-sulfated CCK can cause ulcers by stimulating acid. In healthy individuals, sulfated CCK inhibits acid. This distinction is crucial for understanding gastric pathologies.